Archive


Category: Arcus Biosciences

  • Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs

    Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn’t go as far as the takeover that some market commentators have been predicting. Gilead has exercised options on four drug candidates as part of its $2 billion, 10-year alliance that kicked off last year, with the […]

  • Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push

    Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new role as its head of oncology clinical research. The two companies entered into a 10-year alliance last year, with Gilead claiming certain rights to Arcus clinical and preclinical immuno-oncology candidates […]